Clinical trials
Glucose Metabolism Disorders trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2006 | 7 |
| 2007 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Recruiting | 2 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Takeda | 8 |
| Maastricht University Medical Center | 5 |
| Ultragenyx Pharmaceutical Inc | 5 |
| Diamyd Medical AB | 1 |
| Eli Lilly and Company | 1 |
| Fractyl Health Inc. | 1 |
| Leiden University Medical Center | 1 |
| Maastricht University | 1 |
| Medical Research Foundation, The Netherlands | 1 |
| ModernaTX, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glucose Metabolism Disorders | 29 |
| Diabetes Mellitus | 13 |
| Diabetes Mellitus, Type 2 | 12 |
| Dyslipidemias | 9 |
| Metabolic Diseases | 7 |
| Endocrine System Diseases | 6 |
| Glycogen Storage Disease Type I | 5 |
| Diabetes Mellitus, Type 1 | 4 |
| Glucose Intolerance | 4 |
| Insulin Resistance | 4 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.